SGRY Form 144 Reveals 236,865 Shares Sold Recently; 2,014-Share Sale Planned

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) Form 144: The filing notifies a proposed sale of 2,014 common shares through UBS Financial Services with an aggregate market value of $45,217, to be sold on 09/08/2025. The shares were acquired the same day via equity compensation (equity option exercise) from Surgery Partners, Inc.

The filing also discloses prior sales by Wayne DeVeydt between 08/21/2025 and 09/05/2025 totaling 236,865 common shares for gross proceeds of $5,392,323. The form includes the mandatory representation that the seller is not aware of any undisclosed material adverse information.

Positive

• Clear compliance with Rule 144: planned sale and prior sales are disclosed with dates, amounts and gross proceeds
• Transparency about acquisition method: the 2,014 shares were acquired via equity option exercise
• Prior sales quantified: 236,865 shares sold in the past 3 months with total gross proceeds of $5,392,323

Negative

• Significant insider selling activity in the prior three weeks: 236,865 shares sold, which may concern some investors despite being a small percentage of outstanding shares
• Planned sale occurs immediately after acquisition (same-day exercise and proposed sale on 09/08/2025), which could be interpreted as a quick monetization of compensation

Insights

Financial Analyst

TL;DR: Routine insider report; small planned sale and prior substantial disposals disclosed, totaling 236,865 shares for $5.39M.

The Form 144 documents a planned sale of 2,014 shares acquired by equity option exercise and scheduled for 09/08/2025, routed through UBS. The filing separately lists prior open-market sales by Wayne DeVeydt from 08/21/2025–09/05/2025 amounting to 236,865 shares with gross proceeds of $5,392,323. For investors, the planned sale itself is modest at an aggregate market value of about $45k relative to the company's 128,209,410 shares outstanding. The recent historic sales are the more notable disclosure; they are transparent and comply with Rule 144 reporting obligations.

Corporate Governance Expert

TL;DR: Compliance-focused filing showing exercised options and substantial recent insider disposals; disclosure meets Rule 144 requirements.

The notice shows the seller exercised equity compensation and plans to sell the acquired shares, while affirming no undisclosed material adverse information. Multiple prior sales by an individual (Wayne DeVeydt) are itemized with dates, amounts and gross proceeds, supporting market transparency. The disclosure is procedural and aligns with standard insider sale reporting; it does not itself reveal operational or governance changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	2014	45217	128209410	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/08/2025	equity compensation	Surgery Partners, Inc.			2014	09/08/2025	equity option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/02/2025	25000	562150
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/03/2025	25000	560251
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/04/2025	25000	562756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/05/2025	25000	563682

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Surgery Partners (SGRY) disclose?

The form discloses a proposed sale of 2,014 common shares (aggregate market value $45,217) to be sold on 09/08/2025, acquired via equity option exercise.

How many shares did insiders sell in the past three months according to this filing?

The filing lists prior sales totaling 236,865 common shares between 08/21/2025 and 09/05/2025.

What were the gross proceeds from the prior insider sales?

Gross proceeds from the listed sales in the past three months total $5,392,323.

Who executed the prior sales disclosed in the filing?

The prior sales are attributed to Wayne DeVeydt at the address listed in the form.

Through which broker is the proposed sale to be executed?

The proposed sale of 2,014 shares is to be executed through UBS Financial Services Inc.